At the German Cancer Congress 2016, held in Berlin, Germany from 24 to 27 February 2016, Viktor Grünwald, MD, PhD, from Hannover Medical School, Hannover, Germany, highlights recent advances in the treatment of patients with head and neck cancer, including the increasing interest in immunotherapy with the programmed death (PD-1) inhibitors, pembrolizumab and nivolumab.
Immunotherapy for head and neck cancer
14th June 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?